Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEART-1: HB1011 in Ischemic Cardiomyopathy
NCT07861035Phase 1Recruiting
- Sponsor
- HieraBio
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB1011 in ischemic cardiomyopathy (ICM) (2 arms), sponsored by HieraBio. Primary endpoints: Adverse Events at 12 months and Dose Limiting Toxicity at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
HB1011
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT07861035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861035.